Table 3 Comparison of sensitivity and specificity of a FIT for detection of CRC and advanced adenomas in males and females at different cut-off values
CRC | Advanced adenoma | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Sensitivity | Sensitivity | ||||||||||
FIT cut-off | Total N = 69* | Males N = 45* | Females N = 24* | Difference | p-value | FIT cut-off | Total N = 304 † | Males N = 164 † | Females N = 140 † | Difference | p-value |
50 ng/ml (CI) | 88.4% (78–95) | 93.3% (82–99) | 79.2% (58–93) | 14.1% | 0.12 | 50 ng/ml (CI) | 34.9% (30–41) | 36.6% (39–45) | 32.9% (25–41) | 3.7% | 0.55 |
75 ng/ml (CI) | 85.5% (75–93) | 93.3% (82–99) | 70.8% (49–87) | 22.5% | 0.03 | 75 ng/ml (CI) | 30.9% (26–37) | 32.9% (26–41) | 28.6% (21–37) | 4.3% | 0.46 |
100 ng/ml (CI) | 85.5% (75–93) | 93.3% (82–99) | 70.8% (49–87) | 22.5% | 0.03 | 100 ng/ml (CI) | 28.6% (24–34) | 31.7% (25–39) | 25.0% (18–33) | 6.7% | 0.21 |
200 ng/ml (CI) | 75.4% (64–85) | 80.0% (65–90) | 66.7% (45–84) | 13.3% | 0.25 | 200 ng/ml (CI) | 21.1% (17–26) | 24.4% (18–32) | 17.1% (11–24) | 7.3% | 0.16 |
Specificity | Specificity | ||||||||||
FIT cut-off | Total N = 2,953 # | Males N = 1,312 # | Females N = 1,641 # | Difference | p-value | FIT cut-off | Total N = 2,649 ‡ | Males N = 1,148 ‡ | Females N = 1,501 ‡ | Difference | p-value |
50 ng/ml (CI) | 89.5%(88–91) | 87.3% (85–89) | 91.2% (90–93) | −3,9% | <0,05 | 50 ng/ml (CI) | 92.3% (91–93) | 90.8% (89–92) | 93.4% (92–95) | −2.6% | <0.05 |
75 ng/ml (CI) | 91.5% (90–95) | 90.1% (88–92) | 92.6% (91–94) | −2,5% | <0,05 | 75 ng/ml (CI) | 94.0% (93–95) | 93.4% (92–95) | 94.5% (93–96) | −1.1% | 0.22 |
100 ng/ml (CI) | 92.6% (92–94) | 91.2% (90–93) | 93.7% (92–95) | −2,5% | <0,05 | 100 ng/ml (CI) | 95.0% (94–96) | 94.4% (93–96) | 95.5% (94–97) | −1.1% | 0.24 |
200 ng/ml (CI) | 94.8% (94–96) | 93.6% (21–95) | 95.8% (95–97) | −2,2% | <0,05 | 200 ng/ml (CI) | 96.6% (96–97) | 96.2% (95–97) | 97.0% (96–98) | −0.8% | 0.28 |